

Other version: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC101620/pdf/ac003155.pdf
![]() |
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group |
|
Authors | ![]() | |
Published in | Antimicrobial agents and chemotherapy. 2000, vol. 44, no. 11, p. 3155-3157 | |
Abstract | We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients. | |
Keywords | Anti-HIV Agents/ therapeutic use — Delavirdine/ therapeutic use — Double-Blind Method — Drug Resistance, Microbial — Drug Therapy, Combination — HIV Infections/ drug therapy — HIV Reverse Transcriptase/genetics — HIV-1/drug effects/genetics — Humans — Treatment Outcome — Zidovudine/therapeutic use | |
Identifiers | PMID: 11036040 | |
Full text |
![]() ![]() Other version: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC101620/pdf/ac003155.pdf |
|
Structures | ||
Citation (ISO format) | JOLY, V. et al. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. In: Antimicrobial agents and chemotherapy, 2000, vol. 44, n° 11, p. 3155-3157. https://archive-ouverte.unige.ch/unige:7355 |